全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

Focus–Specific Clinical Profiles in Human African Trypanosomiasis Caused by Trypanosoma brucei rhodesiense

DOI: 10.1371/journal.pntd.0000906

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Diverse clinical features have been reported in human African trypanosomiasis (HAT) foci caused by Trypanosoma brucei rhodesiense (T.b.rhodesiense) giving rise to the hypothesis that HAT manifests as a chronic disease in South-East African countries and increased in virulence towards the North. Such variation in disease severity suggests there are differences in host susceptibility to trypanosome infection and/or genetic variation in trypanosome virulence. Our molecular tools allow us to study the role of host and parasite genotypes, but obtaining matched extensive clinical data from a large cohort of HAT patients has previously proved problematic. Methods/Principal Findings We present a retrospective cohort study providing detailed clinical profiles of 275 HAT patients recruited in two northern foci (Uganda) and one southern focus (Malawi) in East Africa. Characteristic clinical signs and symptoms of T.b.rhodesiense infection were recorded and the degree of neurological dysfunction determined on admission. Clinical observations were mapped by patient estimated post-infection time. We have identified common presenting symptoms in T.b.rhodesiense infection; however, marked differences in disease progression and severity were identified between foci. HAT was characterised as a chronic haemo-lymphatic stage infection in Malawi, and as an acute disease with marked neurological impairment in Uganda. Within Uganda, a more rapid progression to meningo-encephaltic stage of infection was observed in one focus (Soroti) where HAT was characterised by early onset neurodysfunction; however, severe neuropathology was more frequently observed in patients in a second focus (Tororo). Conclusions/Significance We have established focus-specific HAT clinical phenotypes showing dramatic variations in disease severity and rate of stage progression both between northern and southern East African foci and between Ugandan foci. Understanding the contribution of host and parasite factors in causing such clinical diversity in T.b.rhodesiense HAT has much relevance for both improvement of disease management and the identification of new drug therapy.

 References

[1]  Kennedy PGE (2004) Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 113: 496–504. doi: 10.1172/JCI21052
[2]  Blum J, Schmid C, Burri C (2006) Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 97: 55–64. doi: 10.1016/j.actatropica.2005.08.001
[3]  WHO (2006) Human African trypanosomiasis (sleeping sickness): epidemiological update. WER 81: 71–80.
[4]  Buyst H (1974) The epidemiology, clinical features, treatment and history of sleeping sickness on the northern edge of the Luangwa flybelt. Med J Zam 8: 2–12.
[5]  Buyst H (1977) The epidemiology of sleeping sickness in the historical Luangwa valley. Ann Soc Belge Méd Trop 57: 349–359.
[6]  Rickman LR (1974) Investigations into an outbreak of human trypanosomiasis in the lower Luangwa Valley, Eastern Province, Zambia. East Afr Med J 51: 467–487.
[7]  Foulkes JR (1981) Human trypanosomiasis in Africa. BMJ 283: 1172–1174. doi: 10.1136/bmj.283.6300.1172
[8]  Ormerod WE (1961) The epidemic spread of Rhodesian Sleeping Sickness 1908-1960. T Roy Soc Trop Med H 55: 525–538. doi: 10.1016/0035-9203(61)90075-x
[9]  Odiit M, Kansiime F, Enyaru JC (1997) Duration of symptoms and case fatality of sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo, Uganda. East Afr Med J 74: 792–795.
[10]  Ormerod WE (1967) Taxonomy of the Sleeping Sickness Trypanosomes. J Parasitol 53: 824–830. doi: 10.2307/3276780
[11]  Koerner T, De Raadt P, Maudlin I (1995) The 1901 Uganda Sleeping Sickness Epidemic Revisited - a Case of Mistaken Identity. Parasitol Today 11: 303–306. doi: 10.1016/0169-4758(95)80046-8
[12]  Fèvre EM, Coleman PG, Welburn SC, Maudlin I (2004) Reanalyzing the 1900-1920 sleeping sickness epidemic in Uganda. Emerg Infect Dis 10: 567–573. doi: 10.3201/eid1004.020626
[13]  Hide G, Buchanan N, Welburn SC, Maudlin I, Barry JD (1991) Trypanosoma brucei rhodesiense: characterisation of stocks from Zambia, Kenya and Uganda using reptitive DNA probes. Exp Parasitol 72: 430–439. doi: 10.1016/0014-4894(91)90089-F
[14]  Hide G, Tait A, Maudlin I, Welburn SC (1996) The origins, dynamics and generation of Trypanosoma brucei rhodesiense epidemics in East Africa. Parasitol Today 12: 50–55. doi: 10.1016/0169-4758(96)80654-5
[15]  MacLeod A, Welburn S, Maudlin I, Turner CMR, Tait A (2001) Evidence for multiple origins of human infectivity in Trypanosoma brucei revealed by minisatellite variant repeat mapping. J Mol Evol 52: 290–301. doi: 10.1007/s00239-002-5402-6
[16]  Smith DH, Bailey JW (1997) Human African trypanosomiasis in south-eastern Uganda: clinical diversity and isoenzyme profiles. Ann Trop Med Parasit 91: 851–856. doi: 10.1080/00034989760617
[17]  Ross R, Blair DM (1956) Commission for Technical Cooperation in Africa South of the Sahara. Int Sci Com Tryp Res 6th meeting 9–16.
[18]  Foulkes J (1970) Human trypanosomiasis in Zambia. Med J Zam 4: 167–177.
[19]  Blair DM (1939) Human trypanosomiasis in Southern Rhodesia, 1911–1938. T Roy Soc Trop Med H 32: 729–742. doi: 10.1016/s0035-9203(39)90132-x
[20]  MacLean L, Chisi JE, Odiit M, Gibson WC, Ferris V, et al. (2004) Severity of human African trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect Immun 72: 7040–7044. doi: 10.1128/IAI.72.12.7040-7044.2004
[21]  MacLean L, Odiit M, Macleod A, Morrison L, Sweeney L, et al. (2007) Spatially and genetically distinct African Trypanosome virulence variants defined by host interferon-γ response. J Infect Dis 196: 1620–1628. doi: 10.1086/522011
[22]  MacLean L, Odiit M, Sternberg JM (2001) Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis184: 1086–1090. doi: 10.1086/323479
[23]  Fèvre EM, Coleman PG, Odiit M, Magona JW, Welburn SC, et al. (2001) The origins of a new Trypanosoma brucei rhodesiense sleeping sickness outbreak in eastern Uganda. Lancet 358: 625–628. doi: 10.1016/S0140-6736(01)05778-6
[24]  Davison G (1990) National tsetse and trypanosomiasis survey 1987-1989. Ministry of Agriculture, Lilongwe 60.
[25]  Van den Bossche P, Shumba W, Makhambera P (2000) The distribution and epidemiology of bovine trypanosomiasis in Malawi. Vet Parasitol 88: 163–176. doi: 10.1016/S0304-4017(99)00222-8
[26]  WHO (1983) Trypanosomiasis control manual. Geneva: World Health Organization. pp. p1–142.
[27]  Chappuis F, Loutan L, Simarro P, Lejon V, Buscher P (2005) Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 18: 133–146. doi: 10.1128/CMR.18.1.133-146.2005
[28]  Bennett GF (1962) The haematocrit centrifuge for laboratory diagnosis of hematozoa. Can J Zool 40: 124–125. doi: 10.1139/z62-014
[29]  Woo PT (1970) The haematocrit centrifuge technique for the diagnosis of African trypanosomasis. Acta Trop 27: 384–386.
[30]  De Atouguia J, Kennedy P (2000) Neurological aspects of human African trypanosomiasis. In: Davis LE, editor. Oxford: Butterworth-Heinemann. pp. 321–372.
[31]  WHO (1968) Nutritional Anaemias. World Health Organization, Geneva Tech Rep Ser 405: 5–37.
[32]  Johnson-Spear M, Yip R (1994) Haemoglobin difference between black and white women with comparable iron status: justification for race-specific anaemia criteria. Am J Clin Nut 60: 117–121.
[33]  WHO (2001) Iron Deficiency Anaemia: Assessment, Prevention and Control. World Health Organization, Geneva 1–132.
[34]  Teasdale G, Jennett B (1974) Assessment of coma and impaired consciousness: a practical scale. Lancet 2: 81–84. doi: 10.1016/S0140-6736(74)91639-0
[35]  WHO (1998) Control and surveillance of African Trypanosomiasis. World Health Organization, Geneva Tech Rep Series 881: 1–113.
[36]  Cattand P, Miezan B, De Raadt P (1988) Human African trypanosomasis: use of double centrifugation of cerebrospinal fluid to detect trypanosomes. Bull WHO 66: 83–86.
[37]  Willett KC (1966) The ‘trypanosomal chancre’ in Rhodesian sleeping sickness. T Roy Soc Trop Med H 60: 689–690. doi: 10.1016/0035-9203(66)90015-0
[38]  Box GEP, Cox DR (1964) An Analysis of Transformations. J Roy Soc, Ser B (Methodological) 26: 211–252.
[39]  Apted FIC (1970) Clinical manifestations and diagnosis of sleeping sickness. In: Mulligan HW, editor. London: G. Allen, Unwin. pp. 661–683.
[40]  Greenwood BM, Whittle HC (1980) The pathogenesis of sleeping sickness. T Roy Soc Trop Med H 74: 716–725. doi: 10.1016/0035-9203(80)90184-4
[41]  Stich A, Abel PM, Krishna S (2002) Human African Trypanosomiasis. BMJ 325: 203–206. doi: 10.1136/bmj.325.7357.203
[42]  Murray M, Dexter TM (1988) Anaemia in bovine African trypanosomiasis. Acta Trop 45: 389–432.
[43]  Mabbott N, Sternberg J (1995) Bone-Marrow Nitric-Oxide Production and Development of Anemia in Trypanosoma brucei-Infected Mice. Infect Immun 63: 1563–1566.
[44]  Duggan AJ, Hutchinson MP (1966) Sleeping sickness in Europeans: a review of 109 cases. J Trop Med H 69: 124–131.
[45]  Wery M, Mulumba PM, Lambert PH, Kazyumba L (1982) Hematologic manifestation, diagnosis and immunopathology of African Trypanosomiasis. Sem Hematol 19: 83–92.
[46]  Woodruff A, Ziegler J, Hathaway A, Gwata T (1973) Anaemia in African trypanosomiasis and big spleen disease in Uganda. T Roy Soc Trop Med H 67: 329–337. doi: 10.1016/0035-9203(73)90109-0
[47]  Jenkins GC (1979) Effects of trypanosomes on the hematopoietc system. 20th Trypanosomiasis Seminar. pp. 268–270.
[48]  Chisi JE, Misiri H, Zverev Y, Nkhoma A, Sternberg JM (2004) Anaemia in Human African Trypanosomiasis caused by Trypanosoma Brucei Rhodesiense. East Afr Med J 81: 505–507. doi: 10.4314/eamj.v81i10.9232
[49]  Boa Y, Traore M, Doua F, Kouassi-Traore M, Kouassi B, et al. (1988) The different present day clinical picture of human African trypanosomiasis caused by T. b. gambiense. Analysis of 300 cases from a focus in Daloa, Ivory Coast. Bull Soc Pathol Exot Filiales 81: 427–444.
[50]  Gelfand M (1966) The early clinical features of Rhodesian trypanosomiasis with special reference to the “chancre” (local reaction). T Roy Soc Trop Med H 60: 376–379. doi: 10.1016/0035-9203(66)90304-x
[51]  Olweny CL, Chauhan SS, Simooya OO, Bulsara MK, Njelesani EK, et al. (1986) Adult cerebral malaria in Zambia: preliminary report of clinical findings and treatment response. J Trop Med H 89: 123–129.
[52]  Thuma PE, Mabeza GF, Biemba G, Bhat GJ, McLaren CE, et al. (1998) Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. T Roy Soc Trop Med H 92: 214–218. doi: 10.1016/s0035-9203(98)90753-2
[53]  Blum J, Schmid C, Burri C, Hatz C, Olson C, et al. (2009) Cardiac alterations in human African trypanosomiasis (T.b. gambiense) with respect to the disease stage and antiparasitic treatment. PLoS Negl Trop Dis 3: e383. doi: 10.1371/journal.pntd.0000383
[54]  Jones I, Lowenthal M, Buyst H (1975) Electrocardiographic changes in African trypanosomiasis caused by Trypanosoma brucei rhodesiense. T Roy Soc Trop Med H 69: 388–395. doi: 10.1016/0035-9203(75)90194-7
[55]  De Raadt P, Koten J (1968) Myocarditis in Rhodesiense trypanosomiasis. East Afr Med J 45: 128–132.
[56]  Koten J, De Raadt P (1969) Myocarditis in Trypanosoma rhodesiense infections. T Roy Soc Trop Med H 63: 485–489. doi: 10.1016/0035-9203(69)90036-4
[57]  Pentreath VW, Kennedy PGE (2004) Pathogenesis of Human African Trypanosomiasis. In: Maudlin I, Holmes PH, Miles MA, editors. Oxfordshire: CAB International. pp. 283–301.
[58]  Manson-Bahr PEC, Charters AD (1963) Myocarditis in African trypanosomiasis. T Roy Soc Trop Med H 57: 119–121.
[59]  Kellersberger ER (1933) African sleeping sickness. A review of 9000 cases from a Central African clinic. Am J Trop Med 13: 211–236.
[60]  Pépin J, Khonde N (1996) Relapses following treatment of early-stage Trypanosoma brucei gambiense sleeping sickness with a combination of pentamidine and suramin. T R Soc Trop Med H 90: 183–186. doi: 10.1016/s0035-9203(96)90132-7
[61]  WHO (2004) Investing in a comprehensive health sector response to HIV/AIDS: Scaling up treatment and accelerating prevention. Geneva: World Health Organization.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133